SCHEDULE 13G/A: BlackRock Maintains Significant 7.8% Stake in Arcturus Therapeutics, Files Updated Ownership Disclosure
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, confirming its beneficial ownership of 7.8% of Arcturus Therapeutics Holdings Inc. common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,104,537 shares of Arcturus Therapeutics Holdings Inc. common stock.
- This stake represents 7.8% of the company's total outstanding common stock.
- BlackRock holds sole voting power over 2,077,703 shares and sole dispositive power over 2,104,537 shares.
- The filing is an Amendment No. 5 to Schedule 13G, indicating a routine update to a previously reported stake.
- BlackRock certified that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Arcturus Therapeutics.
Sentiment
Score: 5
Explanation: The document is a factual, routine beneficial ownership report (Schedule 13G) and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It simply states BlackRock's passive ownership stake.
Positives
- Confirmation of a significant institutional investor, BlackRock, holding a substantial stake (7.8%) in Arcturus Therapeutics, which can signal confidence in the company's long-term prospects.
- The filing indicates a passive investment, not an activist one, which generally implies stability and a lack of immediate intent to influence corporate control.
Future Outlook
The filing indicates BlackRock's intent to continue holding the shares in the ordinary course of business, without the purpose of changing or influencing control of Arcturus Therapeutics Holdings Inc.
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure of beneficial ownership by a major institutional investor, BlackRock, in a biotechnology company, Arcturus Therapeutics. Such significant passive stakes are common among large asset managers and reflect their portfolio allocation strategies rather than specific operational insights into the company.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | N/A (previous Power of Attorney revoked) | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | New Power of Attorney issued, revoking a previous one dated April 30, 2023, to authorize specific individuals to execute and file ownership or control-person reporting requirements on behalf of BlackRock, Inc. and its subsidiaries. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Policy/Authorization | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, authorizing specific individuals to execute and file various SEC and non-US regulatory ownership reports (e.g., Schedules 13D/G, Forms 3, 4, 5, 13F, 13H, SHO, N-PX) on its behalf and on behalf of its subsidiaries and affiliates. This new Power of Attorney revokes a previous one dated April 30, 2023. | 2025-01-21 | Streamlines the process for BlackRock to comply with global ownership and control-person reporting requirements by centralizing authorization for filing these documents. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can be viewed as a vote of confidence.
- Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previous Power of Attorney that was revoked by the new one. |
| 2025-01-21 | Effective date of the new Power of Attorney issued by BlackRock, Inc. |
| 2025-03-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-04-23 | Date of filing of this Schedule 13G Amendment No. 5. |
Keywords
BlackRock, Arcturus Therapeutics Holdings Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Disclosure, ARCT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.